Garuda - Garba Rujukan Digital

p-Index From 2021 - 2026

4.51

P-Index

This Author published in this journals

All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Folia Medica Indonesiana Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)

Didik Hasmono

Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga

Author-ID : 278212

Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 73 Documents Claim Missing Document

Claim Missing Document

Articles

1 2 3 4 5

Studi Penggunaan Antihipertensi Golongan Angiotensin Receptor Blockers Terhadap Pasien Gagal Ginjal Kronik Stadium V di Rumah Sakit Bhayangkara Surabaya Bura, Ursula Dua Klowe; Hasmono, Didik; Surdijati, Siti; Hartono, Ruddy
Jurnal Farmasi Sains dan Terapan Vol 4, No 2 (2017)
Publisher : Jurnal Farmasi Sains dan Terapan

Chronic renal failure is functional or structural kidney damage for more than 3 (three) months with or without a decrease in the Glomerular Filtration Rate (GFR), manifested as one of the pathological abnormalities or a sign of kidney damage, including blood or urine composition abnormalities or radiology abnormalities. In addition, chronic renal failure is also defined as a condition of GFR value of less than 60 ml / minute / 1.73 m2, for more than 3 (three) months with or without kidney damage. One of the risk factor for chronic renal failure is hypertension. The purpose of antihypertensive administration is to prevent further damage to other organs, and also to reduce blood pressure in patients with chronic renal failure with a target of â‰¤ 140 mmHg. Angiotensin Receptor Blockers (ARB) is a first-line therapy used to reduce blood pressure so that it can delay kidney damage. The purpose of this study was to determine the pattern of antihypertensive drug use in the ARB class in patients with stage V chronic renal failure at Bhayangkara Hospital in Surabaya which was associated with clinical and laboratory data. The study was conducted observationally with a descriptive research design and retrospective data collection. The results showed that those who met the inclusion criteria were 30 patients using antihypertensive ARB therapy, where the highest number of sexes were 67% male and 33% female, the highest populations at the age of 31-70 years, the highest populations was 90% for ARB use and other antihypertensive drug and a single ARB use of 10 %, the most common combination ofantihypertensive group is ARB and Calsium Channel Blocker (CCB) 41%. The patientâ€™s blood pressure mostly meets the target of â‰¤ 140 mmHg.

IDENTIFIKASI PROBLEMA OBAT DALAM PHARMACEUTICAL CARE Yulistiani, .; Suharjono, .; Hasmono, Didik; Khotib, Junaidi; Sumarno, .; Rahmadi, Mahardian; Sidharta, Bambang
Jurnal Farmasi Indonesia Vol 4, No 1 (2008)
Publisher : Jurnal Farmasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfi.v4i1.1

Pharmaceutical care is a colaborative process which goal is to prevent, identify, and solve theÂ drug problem. Pharmacists is the one who responsible to pharmaceutical care, to assure the safety and effectiveness of drug use. This works was aimed to identify and analyze drug problems happened during pharmaceutical care. Data was collected from Dr. Â Syaiful Anwar Hospital Malang, from 1 Januari until 31 August 2006. This was a prospective study (n=138) with descriptive analysis. From the results it can be concluded that drug problems happened during pharmaceutical care in Dr. Syaiful Anwar Hospital Malang consist of: Drug Adverse Reaction (non-elergy side effect 15.22% and toxic effect 3.62%), error in drug choice (untreated indication 18.12%, unappropriate drug to indication 11.59%, unclear drug use 4.35%, unappropriate drug duplication 1.45%), contraindication 0.72%, dosing problem (overtherapy dose 22.46%, overlength therapy 2.90%, subtherapy dose 0.72%), drug interaction (potential interaction 138 cases, manifested interaction 8 cases), and others (patient uncontentment 10.14% and patient unproper care about his/her own disease/therapy 4.35%).Â ABSTRAKPharmaceutical care merupakan proses kolaboratif yang bertujuan untuk mencegah, mengidentifikasi, dan menyelesaikan problema obat. Dalam pelaksanaan, pharmaceutical care merupakan tanggung jawab profesional farmasis untuk menjamin penggunaan obat yang aman dan efektif dalam meningkatkan kualitas hidup pasien. Â Penelitian ini bertujuan untuk mengidentifikasi dan menganalisa problema obat yang terjadi dalam pharmaceutical care. Penelitian dilakukan di Rumah Sakit Umum Dr. Syaiful Anwar Malang periode 1 Januari s/d 31 Agustus 2006, merupakan penelitian observasional-data prospektif (n=138) dengan analisis deskriptif. Dari hasil penelitian dapat disimpulkan bahwa macam problema obat yang terjadi meliputi : Reaksi obat yang tidak dikehendaki terdiri dari: efek samping non alergi (15,22%), efek toksik (3,62%); pemilihan obat terdiri dari: obat tidak diresepkan tetapi indikasi jelas (18,12%), obat tidak sesuai indikasi (11,59%), indikasi penggunaan obat tidak jelas (4,35%),duplikasi obat tidak sesuai (1,45%), Kontraindikasi (0,72%); pemberian dosis terdiri dari: dosis terlalu tinggi (22,46%), durasi terapi terlalu panjang (2,90%), dosis terlalu rendah (0,72%); interaksi obat terdiri dari: interaksi potensial 138 kejadian (n=138), manifestasi interaksi (8 kasus); dan problema lain (ketidakpuasan pasien terhadap terapi yang diberikan (10,14%) dan kurangnya perhatian/kesadaran pasien terhadap kondisi/ penyakitnya (4,35%).

Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19) Donsu, Yosefien Christania; Hasmono, Didik
Pharmacon: Jurnal Farmasi Indonesia Vol 17, No 2 (2020)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v17i2.12359

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. The World Health Organization has declared this disease a pandemic, where the scale of the spread of the disease occurs globally throughout the world. Currently, there is no validated pharmacological treatment for COVID-19 disease, and is still in the clinical trial stage. Azithromycin in conjunction with hydroxychloroquine or chloroquine has been proposed as a treatment that can improve the prognosis of COVID-19. This review aims to describe the mechanism of action and effectiveness of azithromycin in the treatment of COVID-19 patients. The review of the article literature was carried out through internet searches by accessing the database from google scholar, PubMed, and science direct sites. The inclusion criteria in this review are articles using azithromycin in clinical trials and COVID-19 therapy which were published from December 2019 to October 2020. Azithromycin is a macrolide antibacterial and is based on studies having antiviral and immunomodulatory effects. The use of azithromycin can lower viral load when added to hydroxychloroquine in COVID-19 patients based on small-scale clinical studies. Azithromycin used with hydroxychloroquine or chloroquine has shown good results, although it raises concerns about the risk of increased side effects of prolonged QT interval so that monitoring of the heart is needed and proven in a larger number of COVID-19 patients. The decision to use azithromycin must take into account the potential benefits and risks, evaluating the possibility of the drug being more effective than the risks to the patient.

Studi Literatur: Agen Antivirus pada Pasien COVID-19 dengan Penyakit Ginjal Kronis Meiliana, Made Laksmi; Hasmono, Didik
Jurnal Farmasi Sains dan Terapan Vol 8, No 2 (2021): Oktober
Publisher : Jurnal Farmasi Sains dan Terapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33508/jfst.v8i2.3365

At the end of 2019, Wuhan, Hubei Province, reported the first case of a virus similar to pneumonia. The World Health Organization (WHO) reports this outbreak as the Corona virus (COVID-19). Infection with COVID-19 may be more common in people who have chronic kidney disease (CKD). Patients with chronic kidney failure may experience infectious complications due to a weakened immune system and immunosuppressive state. Similarly, they suffer from a chronic systemic inflammatory state, which can contribute to increased morbidity and mortality. Thus, the purpose of this study is to conduct a review of antiviral agents and to summarize recommended antiviral regimens in COVID-19 patients with chronic kidney disease. This article search used Mendeley, Google Scholar, ScienceDirect, and PubMed from the NCBI database in October 2020. The administration of drugs to patients with chronic kidney disease who have been exposed to COVID-19 must be seriously considered. Certain antivirals must be adjusted to avoid deteriorating the patient's kidney condition. Antiviral agents are medications used to treat and prevent COVID-19 infection. Numerous antiviral agents, including ramdesivir, ribavirin, hydroxychloroquine or chloroquine, and umifenovir, must be administered with caution and dose adjustments as necessary in CKD patients exposed to COVID-19.

Postoperative antibiotic therapy patterns in Benign Prostatic Hyperplasia (BPH) patients Aghnia Fuadatul Inayah; Rizki Lisya Nugraha; Didik Hasmono
Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Vol. 5 No. 2 (2020)
Publisher : Universitas Muhammadiyah Malang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22219/farmasains.v5i2.13942

Benign Prostatic Hyperplasia (BPH) is an enlarged prostate disease benign or a condition when the cells are present the prostate gland has an increased proliferation rate. There are several treatment options, including conservative (watchful waiting), medical, and surgery. Antibiotics in BPH cases can be prophylactic antibiotics or empiric antibiotics. This study was an observational study. The samples were BPH patients who received antibiotics for period January - November 2019. The pattern of prophylactic antibiotic use shows that most of the patients received ceftriaxone therapy. Operation on BPH patients is TURP which is an operation classified into surgery with a clean-contaminated category so that prophylactic antibiotics are required. There are two patterns of use for empiric antibiotics in BPH patients: single (88%) and combination (12%). The pattern of single or combined use is given to patients depending on the complications of the disease and the patient's clinical condition. BPH cases occur in men mostly occurs at the age of 60-74 years. Prophylactic antibiotic therapy in BPH patients, namely ceftriaxone 1 gr IV once daily was 48 patients (90.6%), a broad spectrum. Meanwhile, the most use of empirical antibiotics with a single pattern is Ceftriaxone 1 gr IV twice daily (35.6%).

Pengetahuan Profesi Tenaga Kefarmasian Terhadap Terapi dan Rawat Luka Pasien Kanker Mareta Rindang Andarsari; Pharmasinta Putri Hapsari; Marcha Debby Saraswati; Yudistira Nurrizky Grahitaning Putra Rohmaana; Didik Hasmono; Budi Suprapti
Majalah Farmasetika Vol. 6, Supl. 1, Tahun 2021
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24198/mfarmasetika.v6i0.37017

Penderita kanker dengan modalitas terapi kanker dapat mengalami efek samping obat dan luka kanker. Penyelesaian permasalahan dan peningkatan faktor keselamatan pasien terkait penggunaan obat, serta kualitas hidup yang membaik dipengaruhi oleh kerjasama antara tenaga kesehatan, salah satunya tenaga kesehatan farmasi. Pengetahuan tenaga kefarmasian terkait pengobatan dan perawatan yang diberikan pada pasien kanker sangat dibutuhkan untuk menunjang praktek kolaborasi. Tingkat pengetahuan tenaga kefarmasian penting diketahui untuk upaya penguatan sistem pelayanan kesehatan. Penelitian ini bertujuan untuk mengetahui pengetahuan tenaga kesehatan farmasi terhadap terapi dan rawat luka pasien kanker. Penelitian ini adalah penelitian deskriptif, non-random sampling dengan metode accidental sampling. Penelitian dilakukan pada bulan November 2020, pengumpulan data menggunakan survei online. Total 99 orang tenaga kefarmasian yang terdiri dari apoteker dan tenaga teknis kefarmasian mengisi kuesioner tersebut. Selanjutnya dilakukan penilaian pengetahuan pada setiap butir pertanyaan. Sejumlah 71,72% tenaga kefarmasian memiliki pengetahuan yang baik terhadap hal umum terkait terapi dan rawat luka kanker. Lebih dari sembilan puluh persen tenaga kefarmasian dapat menjawab dengan tepat terkait tujuan terapi kanker, penanggulangan efek samping obat, dan keadaan yang diperhatikan saat perawatan luka. Apoteker memiliki pengetahuan yang baik sebesar 74,39% dan tenaga teknis kefarmasian sebesar 58,82%. Tenaga kefarmasian memiliki pengetahuan yang baik terkait perihal dasar terapi kanker dan rawat luka pasien kanker. Apoteker memiliki pengetahuan yang baik terutama perihal efek samping obat dibandingkan tenaga teknis kefarmasian.

Studi Pola Pemberian Artemisinin-Based Combination Therapy pada Pasien Malaria di RSUD Supiori Papua Sandra J. Parambang; Didik Hasmono; Jenggo Suwarko
Indonesian Journal of Clinical Pharmacy Vol 10, No 1 (2021)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2021.10.1.30

Malaria merupakan salah satu penyakit dengan prevalensi tinggi di Indonesia. Data Riset Kesehatan Dasar (Riskesdas) tahun 2018 menunjukkan prevalensi populasi malaria berdasarkan riwayat pemeriksaan darah tertinggi di Indonesia pada tahun 2013–2018 yaitu di Provinsi Papua. Tujuan penelitian adalah mengetahui pola pemberian dan ketepatan terapi Artemisinin based combination therapy (ACT) di RSUD Supiori, Papua. Penelitian ini merupakan penelitian deskriptif dengan pengambilan data secara retrospektif yaitu melakukan penelusuran terapi melalui rekam medis pasien dan dokumen pencatatan yang lain. Penelitian dilakukan pada periode Januari–Agustus 2019 terhadap 1.636 orang dan 71 pasien dinyatakan positif malaria. Seluruh pasien (100%) diterapi dengan Dyhidroartemisinin-piperaquin (DHP). Kasus malaria falciparum ditemukan pada 33 orang (46,48%), dan hampir seluruhnya (96,97%) diterapi dengan DHP+Primakuin. Kasus malaria vivax ditemukan pada 33 orang (46,48%), yang seluruhnya (100%) diterapi dengan DHP+Primakuin. Kasus malaria mix ditemukan pada 5 orang (7,04%), sebanyak 4 orang (80,00%) diterapi dengan DHP+Primakuin dan 1 orang (20,00%) diterapi dengan Artesunate dilanjutkan dengan DHP+Primakuin.Pola pemberian terapi malaria di RSUD Supiori pada periode Januari–Agustus 2019 telah sesuai pedoman tatalaksana malaria. Kata kunci: Artemisinin-based combination therapy (ACT), malaria, pola pemberian terapi Study of Artemisinin-Based Combination Therapy Patterns in Malaria Patients at Supiori Hospital, Papua AbstractMalaria is a disease with high prevalence in Indonesia. According to the Basic Health Research data (Riskesdas) 2018, the province with the highest prevalence of malaria based on the results of blood tests in Indonesia was Papua. The research aims to determine the accuracy of Artemisinin-based combination therapy (ACT) pattern at Supiori Hospital, Papua. Furthermore, a descriptive study and data collection were conducted retrospectively by tracking the treatment history recorded in the patient medical records and other documents. The study was conducted between January–August 2019 and out of 1.636 patients, 71 tested positive for malaria. All patients (100%) were treated with Dyhidroartemisinin-piperaquine (DHP). Falciparum malaria cases were found in 33 people (46.48%), and almost all (96.97%) were treated with DHP+Primaquine. Vivax malaria cases were found in 33 people (46.48%), all of whom (100%) were treated with DHP+Primaquine. Also, mixed malaria cases were found in 5 people (7.04%), 4 people (80.00%) were treated with DHP+Primaquine and 1 person (20.00%) was treated with Artesunate followed by DHP+Primaquine. Furthermore, the pattern of providing malaria therapy at Supiori Hospital in the period January to August 2019 followed the malaria guidelines.Keywords: Artemisinin-based combination therapy (ACT), malaria, pattern of therapy

STUDI PENGGUNAAN CALCIUM CHANNEL BLOCKER (CCB) PADA PASIEN STROKE HEMORRAGHIC Nadriatul Utami; Didik Hasmono; Lilik Yusetyani
Media Farmasi: Jurnal Ilmu Farmasi Vol 10, No 2: September 2013
Publisher : Universitas Ahmad Dahlan

Stroke adalah penyakit yang dapat menyebabkan kematian di dunia. Di Indonesia, dapat menyebabkan stroke yaitu hipertensi sehingga diperlukan antihipertensi, Metode penelitian yang dilakukan yaitu studi observasi dengan menggunakan sampel menunjukkan penggunaan CCB yaitu nicardipine 64%, nimodipine 12%, amlodipine 2%, dan diltiazem 6%. salah satunya adalah golongan Calcium Channel Blocker (CCB). Maksud penelitian ini yaitu meneliti penggunaan CCB pada pasien dengan hemorrhagicstroke hospitalizations di Rumah Sakit Umum (RSU) Dr. Saiful Anwar Malang.retrospective descriptive method. Analisis dilakukan pada Bulan Januari sampai Desember 2012 pada medical records pasien yang didiagnosa menderita strokehemorrhagic dan menerima pengobatan CCB. Hasil dan Kesimpulan dari 54 jumlah pasien yang menderita stroke mencapai 8,3%. Faktor resiko terbesar yang

PENGGUNAAN OBAT GOLONGAN DIURETIK PADA PASIEN STROKE ISKEMIK DI INSTALASI RAWAT INAP RSU DR. SAIFUL ANWAR MALANG Widi Astutik; Didik Hasmono; Nailis Syifa
Media Farmasi: Jurnal Ilmu Farmasi Vol 10, No 2: September 2013
Publisher : Universitas Ahmad Dahlan

Stroke iskemik adalah sindrom yang berupa gejala hilangnya fungsi sistem saraf pusat yang berkembang pesat dapat karena atherothrombotis atau emboli, yang keduanya dapat mengganggu aliran darah serebral (CBF). Pemilihan terapi antihipertensi yang sesuai pada pasien stroke sangat berpengaruh dalam keberhasilan terapi yang dilakukan. Diuretik efektif untuk mengurangi tekanan intrakranial. Penelitian ini bertujuan untuk mengetahui pola penggunaan obat diuretik pada pasien stroke iskemik di RSU Dr Saiful Anwar Malang dan meninjau hubungan terapeutik terkait jenis obat, dosis, cara pemberian, interval, frekuensi, dan durasi dengan data klinis dan data laboratorium pasien. Penelitian ini merupakan penelitian observasional dan data dikumpulkan secara retrospektif pada pasien stroke iskemik dari 1 Juli hingga 31 Desember 2012. Profil diuretik tunggal yang digunakan adalah mannitol. Kombinasi diuretik yang ditemukan adalah furosemid dan spironolacton. Penggunaan terapi diuretik pada pasien dengan stroke iskemik sudah sesuai dengan pedoman.

Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19) Yosefien Christania Donsu; Didik Hasmono
Pharmacon: Jurnal Farmasi Indonesia Vol 17, No 2 (2020)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v17i2.12359

Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningrum , Yunita Dyah Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Nadriatul Utami Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka

Title

Found 73 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 73 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 73 Documents
Search